Iberdomide History and Updates

112 events · 2020 – present

Synced daily from openFDA and ClinicalTrials.gov. Last sync: .

0
FDA Approvals
0
Label Revisions
112
Trial Milestones
0
Pivotal Publications
Iberdomide — history and updatesFDA approvals, label revisions, recalls, trials, and pivotal publicationsFDA approvalsLabel revisionsRecalls + safetyTrialsPublications20202021202220232024202520262027202820292030203120322033203420352036Trial: NCT07437963 2026-07-30 → 2029-09-30 (primary completion)Trial: NCT07601100 2026-06-26 → 2029-07-01 (primary completion)Trial: NCT07624513 2026-06-08 → 2033-10-01 (primary completion)Trial: NCT06896916 2025-08-07 → 2036-03-31 (primary completion)Trial: NCT06348108 2025-07-28 → 2027-07-31 (primary completion)Trial: NCT06762769 2025-06-02 → 2032-11-30 (primary completion)Trial: NCT06232044 2025-04-23 → 2028-05-01 (primary completion)Trial: NCT06785415 2025-03-18 → 2031-04-01 (primary completion)Trial: NCT05272826 2024-12-12 → 2028-03-31 (primary completion)Trial: NCT06465316 2024-12-06 → 2026-12-31 (primary completion)Trial: NCT06518551 2024-11-01 → 2029-12-31 (primary completion)Trial: NCT06179888 2024-08-27 → 2027-10-31 (primary completion)Trial: NCT06216158 2024-04-05 → 2028-12-31 (primary completion)Trial: NCT06121843 2024-02-22 → 2028-08-01 (primary completion)Trial: NCT05896228 2024-02-20 → 2029-03-01 (primary completion)Trial: NCT06215118 2024-02-20 → 2027-04-10 (primary completion)Trial: NCT06107738 2023-12-21 → 2025-12-31 (primary completion)Trial: NCT05583617 2023-11-14 → 2028-07-31 (primary completion)Trial: NCT05827016 2023-06-22 → 2029-03-15 (primary completion)Trial: NCT05899738 2023-05-18 → 2023-07-06 (primary completion)Trial: NCT05560399 2023-02-06 → 2026-11-30 (primary completion)Trial: NCT05434689 2023-01-18 → 2028-08-31 (primary completion)Trial: NCT05558319 2022-10-31 → 2027-04-30 (primary completion)Trial: NCT05169515 2022-10-26 → 2029-09-15 (primary completion)Trial: NCT05527340 2022-09-30 → 2029-12-31 (primary completion)Trial: NCT05392946 2022-08-11 → 2026-09-29 (primary completion)Trial: NCT04975997 2022-06-23 → 2027-11-16 (primary completion)Trial: NCT05199311 2022-05-13 → 2026-06-30 (primary completion)Trial: NCT05289492 2022-05-01 → 2023-11-29 (primary completion)Trial: NCT05354557 2022-04-26 → 2027-04-26 (primary completion)Trial: NCT05177536 2022-04-15 → 2026-01-31 (primary completion)Trial: NCT04998786 2021-12-14 → 2030-01-01 (primary completion)Trial: NCT04933747 2021-08-12 → 2023-01-23 (primary completion)Trial: NCT04776395 2021-07-09 → 2027-09-01 (primary completion)Trial: NCT04564703 2021-02-22 → 2023-07-27 (primary completion)Trial: NCT04392037 2021-02-17 → 2027-12-31 (primary completion)today (2026-06-12)FDA approvalLabel revisionRecall or safetyTrial activityPivotal publication

Source: openFDA, ClinicalTrials.gov via AACT, PubMed · Hipa.ai, 2026-06-12Download chart as PNG

This page tracks every FDA action, clinical trial milestone, and major publication for Iberdomide since 2020, drawn from openFDA, ClinicalTrials.gov, and PubMed.

Upcoming & expected milestones

Trial started· ClinicalTrials.gov
Phase 1/Phase 2 trial started: NCT07437963
Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT06465316
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT06465316
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT06215118
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Mu
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT05354557
Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT04776395
Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
Primary completion· ClinicalTrials.gov
Phase 3 primary completion: NCT04975997
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Par
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT06121843
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participa
Primary completion· ClinicalTrials.gov
Phase 3 primary completion: NCT06216158
Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT05896228
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
Primary completion· ClinicalTrials.gov
Phase 3 primary completion: NCT05827016
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT05169515
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in P
Primary completion· ClinicalTrials.gov
Phase 1/Phase 2 primary completion: NCT07437963
Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT05527340
Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT04998786
A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse
Primary completion· ClinicalTrials.gov
Phase 3 primary completion: NCT07624513
Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and M
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT06896916
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Advers

Past events

2026
Trial started· ClinicalTrials.gov
Phase 3 trial started: NCT07624513
Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and M
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT05354557
Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)
2025
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT06107738
Iberdomide and Daratumumab As Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT06896916
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Advers
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT06348108
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Trial started· ClinicalTrials.gov
Phase 1/Phase 2 trial started: NCT06232044
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
2024
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT05272826
Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT06465316
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT06179888
Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
Trial started· ClinicalTrials.gov
Phase 3 trial started: NCT06216158
Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT06121843
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participa
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT05896228
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT06215118
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Mu
2023
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT06107738
Iberdomide and Daratumumab As Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT05899738
A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels
Trial started· ClinicalTrials.gov
Phase 3 trial started: NCT05827016
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT05899738
A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels
Trial started· ClinicalTrials.gov
EARLY_Phase 1 trial started: NCT05560399
A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT04933747
Study to Evaluate Safety and Tolerability of Iberdomide (CC-220) in Participants With Kidney Impairment Compared to Participants With Normal
2022
Trial started· ClinicalTrials.gov
Phase 3 trial started: NCT05558319
NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT05169515
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in P
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT05527340
Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.
Trial started· ClinicalTrials.gov
Phase 3 trial started: NCT04975997
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Par
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT05354557
Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)
2021
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT04998786
A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT04933747
Study to Evaluate Safety and Tolerability of Iberdomide (CC-220) in Participants With Kidney Impairment Compared to Participants With Normal
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT04776395
Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
2020

Sources

FDA approvals, label revisions, and recalls come from the public openFDA APIs (Drugs@FDA, Drug Label, Drug Enforcement). Drug-safety communications come from the FDA RSS feed. Trial milestones come from ClinicalTrials.gov via the AACT pg dump. Pivotal-publication events come from PubMed, filtered to high-impact journals linked to a Phase 3 trial in our inventory.